RPS6KA4

Across TCGA pan-cancer cohorts, RPS6KA4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPS6KA4 data layer compared with 30 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RPS6KA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS6KA4 expression acts as an unfavorable survival marker.

SKCM, PRAD, and UCEC are the cancer types where RPS6KA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.712	0.880	.002	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPS6KA4–SKCM (OS)

Open the SKCM breakdown →